List of Excipients in Branded Drug DOPAMINE HYDROCHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Henry Schein Inc	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	0404-9981	ANHYDROUS CITRIC ACID
Henry Schein Inc	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	0404-9981	SODIUM METABISULFITE
Henry Schein Inc	DOPAMINE HYDROCHLORIDE	dopamine hydrochloride	0404-9981	TRISODIUM CITRATE DIHYDRATE

Generic Drugs Containing DOPAMINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	dopamine hydrochloride	0143-9252	CITRIC ACID ACETATE
Hikma Pharmaceuticals USA Inc	dopamine hydrochloride	0143-9252	SODIUM CITRATE
Hikma Pharmaceuticals USA Inc	dopamine hydrochloride	0143-9252	SODIUM METABISULFITE

What are the Most Frequently-Used Excipients in DOPAMINE HYDROCHLORIDE?

# Of NDCs	Excipient
5	CITRIC ACID ACETATE
5	SODIUM CITRATE
5	SODIUM METABISULFITE

Dopamine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Dopamine hydrochloride is a mature, multisource injectable drug with limited patent protection and low formulation complexity. Commercial differentiation depends on supply reliability, ready-to-use presentation, container-closure performance, cold-chain avoidance, and hospital workflow economics rather than on new chemical-entity exclusivity. The strongest opportunities are premixed bags, standardized high-concentration presentations, dual-chamber or syringe formats, and improved manufacturing resilience for critical-care shortages.

What is the FDA regulatory status of dopamine hydrochloride injection?

Dopamine hydrochloride is an FDA-approved vasopressor and inotropic agent administered by continuous intravenous infusion. It is indicated for hemodynamic support in selected patients with distributive or cardiogenic shock and is dosed according to clinical response and infusion rate.[1]

FDA dosage forms and strengths

Commercial dopamine hydrochloride products are generally supplied as:

Presentation	Typical strength	Administration	Commercial role
Concentrated sterile injection	40 mg/mL	Dilution before infusion	Lower freight volume; pharmacy compounding
Concentrated sterile injection	80 mg/mL	Dilution before infusion	Higher-dose ICU use
Premixed IV bag	400 mg/250 mL	Ready for infusion after connection to pump	Reduced preparation burden
Premixed IV bag	800 mg/500 mL	Ready for infusion after connection to pump	Common hospital concentration
Pharmacy bulk or specialty presentations	Varies	Institutional preparation	Limited, site-specific use

The exact marketed strengths vary by manufacturer and product discontinuation status. Product labels and FDA databases control the regulatory status of individual National Drug Codes.

Dopamine hydrochloride is a small-molecule generic drug, not a biologic. Biosimilar pathways do not apply. Regulatory competition occurs through abbreviated new drug applications, manufacturing capacity, drug-shortage positioning, and formulation or container improvements.

What excipients are used in dopamine hydrochloride formulations?

The core excipient strategy is built around chemical stability, pH control, osmolarity, sterility, and compatibility with intravenous administration.

Typical excipient architecture

Excipient or vehicle	Primary function	Strategic importance
Water for Injection	Solvent	Required for sterile parenteral manufacture
Sodium chloride	Tonicity adjustment	Used in selected concentrate formulations
Dextrose	Vehicle and tonicity agent	Common in ready-to-use premixed solutions
Sodium metabisulfite	Antioxidant	Controls oxidative degradation where included in the approved formulation
Hydrochloric acid or sodium hydroxide	pH adjustment	Maintains acidic stability range
Nitrogen overlay or low-oxygen processing	Oxidation control	Manufacturing and packaging measure rather than label excipient
Container-closure materials	Protection from oxygen, light, and adsorption	Critical for shelf life and extractables control

Dopamine is chemically vulnerable to oxidation. Oxidative degradation can produce discoloration and loss of potency. Approved labeling generally instructs protection from light and requires visual inspection before administration.[1,2]

Why sodium metabisulfite matters

Sodium metabisulfite can reduce oxidative degradation in concentrated dopamine solutions. Its inclusion creates a tradeoff:

• It can improve chemical stability and support a commercially useful shelf life.
• It introduces sulfite exposure that must be declared in labeling.
• It may create sensitivity concerns in susceptible patients.
• It can complicate customer positioning where hospitals prefer sulfite-free products.

A sulfite-free formulation may have commercial value, but it must demonstrate equivalent stability through oxygen control, pH optimization, container selection, headspace management, and validated manufacturing controls. Removing the antioxidant without replacing its stability function is not a viable product strategy.

What formulation patents protect dopamine hydrochloride?

Dopamine hydrochloride has a weak patent estate compared with newer injectable drugs. The active ingredient has been used clinically for decades, and the principal commercial products are generic sterile injections.

Patent position

The relevant protection categories are:

1. Formulation and stabilization claims.
2. Ready-to-use premixed infusion products.
3. Container-closure systems.
4. Manufacturing processes that control oxidation or particulate formation.
5. Device claims covering prefilled syringes, infusion systems, or automated compounding.

The original compound and core therapeutic use are long expired. Current commercial products generally compete without an active composition-of-matter patent barrier. Orange Book-listed patent protection for dopamine hydrochloride injection is not generally the principal constraint on market entry; the practical barriers are FDA approval, sterile manufacturing validation, product quality, and reliable supply.[3]

A company pursuing a new dopamine presentation should conduct a current Orange Book and patent-family review before filing. Potentially relevant patents may sit outside the Orange Book if they cover manufacturing, packaging, delivery devices, or hospital-use systems rather than the approved drug product itself.

How strong is the dopamine hydrochloride patent estate?

Patent category	Strength	Commercial effect
Active ingredient	Expired or commercially irrelevant	No meaningful exclusivity
Basic injectable formulation	Weak	Multiple generic competitors
Premixed IV product	Moderate only if claims are narrow and technically specific	Possible differentiation, limited blocking power
Antioxidant-free formulation	Potentially meaningful	Requires strong stability and non-obviousness evidence
Container or syringe system	Moderate	Can support product differentiation
Manufacturing process	Variable	Usually difficult to enforce against competitors
Method of use	Weak for standard shock indications	Most clinical uses are established

When does dopamine hydrochloride lose exclusivity?

Dopamine hydrochloride has already lost regulatory and patent exclusivity. The product is a mature generic injectable rather than a protected branded medicine.

Exclusivity timeline

Event	Approximate status
Original clinical introduction	1960s
FDA approval of early branded dopamine products	1970s
Compound patent exclusivity	Expired decades ago
Generic injectable competition	Established
Current market status	Multisource generic
New-product exclusivity	Available only through a qualifying new drug, device, or regulatory pathway, not through the legacy active ingredient

A new dopamine hydrochloride product could potentially obtain limited regulatory exclusivity only if it qualifies under a separate statutory pathway, such as a new drug application with a qualifying clinical or formulation innovation. A routine abbreviated new drug application does not create broad market exclusivity.

What is the Orange Book status of dopamine hydrochloride?

The FDA Orange Book identifies approved drug products, reference-listed drugs, therapeutic equivalence information, and applicable patent or exclusivity data.[3]

Dopamine hydrochloride injection is generally represented as a multisource prescription injectable with multiple approved manufacturers and strengths. The Orange Book is most relevant for:

• Confirming the reference-listed drug.
• Reviewing therapeutic-equivalence codes.
• Identifying approved dosage forms and strengths.
• Checking whether any product-specific patents or exclusivities remain.
• Assessing whether a proposed generic can reference an existing injectable product.

Because the market includes discontinued and active products, an applicant must distinguish historical approvals from currently marketed products. A discontinued reference product may still support an ANDA if FDA identifies it as the appropriate reference standard, but product selection and bioequivalence strategy require regulatory review.

What excipient strategy creates commercial value?

The best excipient strategy depends on the intended presentation.

Concentrated ampoule or vial

A concentrated product is designed for hospital pharmacy dilution. The formulation priorities are:

• Low degradation during shelf storage.
• Low particulate burden.
• Compatible pH.
• Small fill volume.
• Reliable withdrawal from the container.
• Clear labeling of final dilution requirements.
• Resistance to oxygen ingress.

Sodium metabisulfite may be appropriate where the stability package supports its use. A low-volume, high-strength vial can reduce storage and shipping costs, but it increases medication-error risk if concentration labeling is not prominent.

Premixed dextrose bag

A premixed bag removes dilution and compounding steps. Its commercial benefits include:

• Faster availability during emergencies.
• Reduced pharmacy workload.
• Lower dilution-error risk.
• Standardization of infusion concentrations.
• Better fit with automated medication-management systems.

Dextrose-based vehicles are common because they provide a compatible infusion medium and help establish suitable tonicity. The manufacturer must control pH, oxygen exposure, bag permeability, light transmission, and interaction between the drug solution and the polymer film.

Sodium chloride premix

A saline-based product can address hospitals that standardize critical-care infusions in sodium chloride. The opportunity is commercially credible, but the formulation must establish:

• Chemical stability in the selected salt concentration.
• Compatibility with the bag film and administration set.
• Osmolality acceptable for the intended route and infusion conditions.
• No clinically relevant precipitation or discoloration.

A saline presentation may also be attractive where institutions seek to reduce dextrose exposure. It should not be positioned as interchangeable with every existing dopamine product without confirming labeling and concentration requirements.

Prefilled syringe

A prefilled syringe could target emergency departments, transport teams, operating rooms, and intensive-care settings. Its value is operational rather than pharmacological:

• Faster deployment.
• Reduced preparation time.
• Lower manipulation burden.
• Improved dose-concentration consistency.
• Compatibility with syringe pumps.

The principal technical risks are oxygen ingress, syringe-material compatibility, extractables and leachables, plunger movement, dose accuracy, and shelf-life limitations. A prefilled syringe may support stronger commercial differentiation than another conventional vial, but development and packaging costs are higher.

What manufacturing and IP barriers affect dopamine hydrochloride?

The main barriers are process and quality barriers, not active-ingredient patents.

Oxidation control

Manufacturers should evaluate:

• Dissolved oxygen at bulk and fill stages.
• Nitrogen purging and headspace composition.
• Antioxidant concentration.
• Solution pH.
• Light exposure.
• Mixing order and hold time.
• Bulk-solution residence time.
• Temperature excursions.

The manufacturing process should connect these parameters to impurity formation and potency loss. A narrow pH window may produce a better stability profile but can affect tolerability, container compatibility, and manufacturing robustness.

Container-closure system

Polyolefin bags, glass vials, plastic syringes, and multilayer infusion containers have different oxygen-transmission and adsorption profiles. The packaging system should be selected with consideration of:

• Oxygen permeability.
• Light protection.
• Drug adsorption.
• Closure integrity.
• Sterilization method.
• Extractables and leachables.
• Compatibility with standard infusion tubing.

A packaging design that materially extends shelf life or removes the need for refrigeration can create a stronger commercial proposition than a minor excipient change.

Sterile manufacturing

Dopamine is an injectable product, so the commercial threshold includes validated aseptic processing or terminal sterilization, depending on the formulation and container. Key risks include:

• Visible and subvisible particulate matter.
• Endotoxin contamination.
• Sterility failures.
• Container-closure defects.
• Fill-volume variability.
• Color changes caused by oxidation.
• Supply interruptions for specialized bags, stoppers, or antioxidants.

FDA drug-shortage records show that injectable products can experience supply pressure even when the active ingredient is old and widely known.[4] Manufacturing redundancy is therefore a commercial asset.

Which companies are challenging or competing with dopamine hydrochloride products?

Dopamine hydrochloride is generally supplied by generic injectable manufacturers, contract manufacturers, and hospital-focused pharmaceutical companies. Competitive activity is driven by product availability rather than by branded clinical differentiation.

The relevant competitive groups include:

• Large generic injectable suppliers.
• Hospital-pharmacy manufacturers.
• Contract development and manufacturing organizations.
• Specialty suppliers focused on ready-to-administer products.
• Regional manufacturers with government or hospital contracts.

The most important competitive variables are:

Variable	Commercial impact
FDA-approved strength range	Determines formulary eligibility
Ready-to-use status	Reduces pharmacy labor
Shelf life	Affects inventory and waste
Supply reliability	Critical for ICU products
Shortage history	Influences contracting decisions
Bag and syringe formats	Supports workflow differentiation
Unit price	Important in tender and group-purchasing contracts
Distribution reach	Determines hospital access

No established biosimilar competitor exists because dopamine hydrochloride is not a biologic. The competitive threat is generic substitution and institutional formulary switching.

What generic entry risks exist?

Generic entry risk is already realized. The market has no meaningful protection from conventional generic competition.

For a new entrant, the risks are different:

1. A crowded multisource market may limit pricing power.
2. Hospitals may resist switching from established suppliers.
3. A shortage-driven opportunity may disappear when incumbent capacity returns.
4. A new presentation may require additional labeling, stability, and human-factors work.
5. A premium price may be difficult to sustain without measurable workflow savings.
6. Concentration errors may create regulatory and liability exposure.
7. A novel container may introduce qualification delays at hospitals.

A generic launch is most credible when it combines a competitive price with a clear operational improvement, such as a ready-to-use bag, longer labeled shelf life, or dependable supply.

What licensing deals could support a dopamine hydrochloride product?

Licensing opportunities are more likely to involve manufacturing and distribution than molecule ownership.

Potential structures include:

• Exclusive regional distribution for a ready-to-use dopamine product.
• Contract manufacturing with a sterile injectable specialist.
• Co-development of a prefilled syringe.
• Hospital-system supply agreements.
• Private-label manufacturing for group-purchasing organizations.
• In-licensing of a validated container-closure platform.
• Portfolio agreements covering dopamine with norepinephrine, epinephrine, and phenylephrine.

A portfolio approach may improve commercial efficiency because hospitals often purchase multiple critical-care injectables from the same supplier. Dopamine alone may not justify a major licensing program unless it fills a shortage gap or is bundled with other ICU products.

What revenue exposure and commercial opportunities exist?

Dopamine hydrochloride is unlikely to support high-margin branded-drug economics. Its revenue opportunity is volume-based and tied to institutional purchasing.

Higher-value opportunities

Ready-to-use products

Premixed bags and prefilled syringes can command a premium if they reduce pharmacy preparation, wastage, and medication-error risk.

Supply reliability

Hospitals may accept a modest premium for a dependable second source, especially for products with shortage histories. Reliability must be demonstrated through manufacturing capacity, inventory policy, and distribution performance.

Portfolio contracting

A supplier that combines dopamine with other vasopressors can compete for broader hospital contracts. This reduces dependence on a single low-price product.

Geographic expansion

Markets with limited sterile-injectable manufacturing may provide opportunities for local fill-finish, government procurement, or regional distribution. Regulatory requirements differ by jurisdiction, and a U.S. FDA approval does not automatically authorize sale elsewhere.

Hospital-premix outsourcing

A qualified manufacturer can target institutions seeking to reduce in-house compounding. The business case depends on state pharmacy rules, outsourcing-facility requirements where applicable, and hospital purchasing economics.

How does dopamine hydrochloride compare with other vasopressors?

Drug	Typical role	Formulation opportunity	Competitive position
Dopamine hydrochloride	Inotropic and vasopressor support	Premix, syringe, concentration standardization	Mature generic
Norepinephrine bitartrate	First-line vasopressor in many shock protocols	Ready-to-use bags and syringes	Higher clinical demand
Epinephrine	Resuscitation and hemodynamic support	Prefilled syringes, autoinjector-adjacent systems	Broad emergency use
Phenylephrine hydrochloride	Vasoconstriction and anesthesia use	Premix and prefilled formats	Strong institutional demand
Vasopressin	Adjunct vasopressor	Ready-to-use presentations	Different regulatory and pricing profile

Dopamine may be less attractive than norepinephrine for a standalone commercial investment because treatment guidelines and institutional protocols often favor norepinephrine for many shock settings.[5] Dopamine remains relevant where heart-rate, cardiac-output, or specific hemodynamic considerations influence product selection.

What is the outlook for dopamine hydrochloride commercial development?

The strongest development strategy is a differentiated sterile product rather than a new conventional vial. Priorities should be:

1. Ready-to-use delivery.
2. Robust oxidation control.
3. Long room-temperature shelf life.
4. Low particulate and container-interaction risk.
5. Clear concentration labeling.
6. Compatibility with hospital infusion systems.
7. Manufacturing redundancy.
8. Portfolio integration with other critical-care injectables.

A new excipient alone is unlikely to create durable commercial protection. The defensible value is more likely to come from the combined formulation, container, manufacturing process, presentation, and supply network.

Key Takeaways

• Dopamine hydrochloride is a mature generic injectable with no meaningful composition-of-matter exclusivity.
• The main formulation problem is oxidation, not solubility.
• Sodium metabisulfite, acidic pH, oxygen control, light protection, and suitable container systems are central to product stability.
• Premixed bags and prefilled syringes offer the clearest commercial differentiation.
• FDA and Orange Book status support generic competition; biosimilar competition does not apply.
• Patent value is likely to be limited to narrow formulation, packaging, manufacturing, or delivery claims.
• Revenue opportunities depend on hospital workflow savings, shortage resilience, portfolio contracting, and reliable sterile manufacturing.
• A conventional low-price vial faces limited strategic upside unless it solves a supply or availability problem.

FAQs

Can dopamine hydrochloride be formulated without sodium metabisulfite?

Yes, but the formulation must replace the antioxidant function through validated oxygen control, pH selection, container design, and stability testing. A sulfite-free product may have a labeling and market-positioning advantage, but it is not automatically more stable or easier to approve.

Is dopamine hydrochloride compatible with normal saline?

Compatibility depends on the specific concentration, vehicle, container, administration set, and approved labeling. A manufacturer cannot rely solely on general compendial compatibility assumptions when developing a commercial premix.

Does a premixed dopamine bag need a new patent?

No. A premixed bag can be approved through an applicable FDA pathway without a patent. Patent protection may be pursued for a technically distinctive formulation, container, or delivery system, but regulatory approval and patent protection are separate issues.

Can dopamine hydrochloride be sold in a prefilled syringe?

Yes, subject to formulation, container-closure, stability, sterility, dose accuracy, labeling, and device-related requirements. The syringe presentation may offer greater commercial differentiation than a conventional vial.

Is dopamine hydrochloride a good candidate for a 505(b)(2) product?

A 505(b)(2) strategy may be relevant for a materially different presentation or delivery system, but the commercial rationale must justify the additional development and regulatory burden. A routine generic formulation is more likely to fit an ANDA pathway.

References

1. U.S. Food and Drug Administration. (2023). Dopamine hydrochloride injection prescribing information. DailyMed, National Library of Medicine.

2. National Library of Medicine. (2024). Dopamine hydrochloride injection: Drug label information. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024). FDA drug shortages database. Center for Drug Evaluation and Research.

5. Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., McIntyre, L., Ostermann, M., Prescott, H. C., Schorr, C., Simpson, S., Wiersinga, W. J., Alshamsi, F., Angus, D. C., Arabi, Y., Azevedo, L., Beale, R., Beilman, G., ... Levy, M. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 47, 1181-1247.